Review assesses the safety limits and translational gaps of MCL-1 degradation strategies
Academic source · Frontiers in Pharmacology
Source published: · Event / reporting date: 2026-11-06
Site published: 2026-11-07 · Updated: 2026-11-07
This source is linked automatically. Choose a question to get started.
What the paper reports
A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.
Why this paper is included
Analysis: The review may help prioritize selectivity, cardiac monitoring, and translational biomarkers before treating MCL-1 degradation as a clinically established resistance strategy.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Edited by the Biotech Assistant content team and reviewed by an authorized publisher. Editorial standards and corrections